Qinghong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qinghong Zhang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Jing Wang
Department of Pathology and Laboratory Medicine, School of Medicine, University of California-Davis, Davis, CA 95817, USA
5 shared publications Gangwen Han
Department of Pathology, University of Colorado Denver, Aurora, CO 80045
4 shared publicationsYu Deng
Department of Dermatology, University of Colorado Denver, Aurora, CO 80045
4 shared publicationsHui Deng
Department of Dermatology, University of Colorado Denver, Aurora, CO 80045
3 shared publicationsJing Liu
Department of Dermatology, University of Colorado Denver, Aurora, CO 80045
3 shared publicationsDonna Wang
Department of Pathology, University of Colorado Denver, Aurora, CO 80045
2 shared publications
Latest Publications
- Open Access
- 1 June 2015
- Published by Elsevier in SLAS Discovery
- Vol. 20 (5) , 663-672
Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression
- 1 June 2015
- Published by Elsevier in SLAS Discovery
- Vol. 20 (5) , 663-672
Open AccessSmall Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression
- Open Access
- 1 May 2014
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (5) , 1323-1331
CtBP1 Overexpression in Keratinocytes Perturbs Skin Homeostasis
- 1 May 2014
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (5) , 1323-1331
Open AccessCtBP1 Overexpression in Keratinocytes Perturbs Skin Homeostasis
- Open Access
- 1 May 2013
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 133 (5) , 1294-1301
CtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1
- 1 May 2013
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 133 (5) , 1294-1301
Open AccessCtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1
- Open Access
- 10 March 2013
- Published by Springer Nature in Nature Medicine
- Vol. 19 (4) , 421-428
Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis
We report that K5.Smad7 mice, which express a Smad7 transgene under the control of a keratin 5 promoter, were resistant to radiation-induced oral mucositis, a painful oral ulceration. In addition to nuclear factor κB (NF-κB) activation, which is known to contribute to oral mucositis, we found activated transforming growth factor β (TGF-β) signaling in cells from this condition. Smad7 dampened both pathways to attenuate inflammation, growth inhibition and apoptosis. Additionally, Smad7 promoted oral epithelial migration to close the wound. Further analyses revealed that TGF-β signaling Smads and their co-repressor C-terminal binding protein 1 (CtBP1) transcriptionally repressed Rac1, and that Smad7 abrogated this repression. Knocking down Rac1 expression in mouse keratinocytes abrogated Smad7-induced migration. Topical application of Smad7 protein conjugated with a cell-permeable Tat tag to oral mucosa showed prophylactic and therapeutic effects on radiation-induced oral mucositis in mice. Thus, we have identified new molecular mechanisms involved in oral mucositis pathogenesis, and our data suggest an alternative therapeutic strategy to block multiple pathological processes in this condition.
- 10 March 2013
- Published by Springer Nature in Nature Medicine
- Vol. 19 (4) , 421-428
Open AccessPreventive and therapeutic effects of Smad7 on radiation-induced oral mucositis
We report that K5.Smad7 mice, which express a Smad7 transgene under the control of a keratin 5 promoter, were resistant to radiation-induced oral mucositis, a painful oral ulceration. In addition to nuclear factor κB (NF-κB) activation, which is known to contribute to oral mucositis, we found activated transforming growth factor β (TGF-β) signaling in cells from this condition. Smad7 dampened both pathways to attenuate inflammation, growth inhibition and apoptosis. Additionally, Smad7 promoted oral epithelial migration to close the wound. Further analyses revealed that TGF-β signaling Smads and their co-repressor C-terminal binding protein 1 (CtBP1) transcriptionally repressed Rac1, and that Smad7 abrogated this repression. Knocking down Rac1 expression in mouse keratinocytes abrogated Smad7-induced migration. Topical application of Smad7 protein conjugated with a cell-permeable Tat tag to oral mucosa showed prophylactic and therapeutic effects on radiation-induced oral mucositis in mice. Thus, we have identified new molecular mechanisms involved in oral mucositis pathogenesis, and our data suggest an alternative therapeutic strategy to block multiple pathological processes in this condition.
- 16 June 2011
- Published by Wiley in Molecular Carcinogenesis
- Vol. 51 (6) , 500-507
Transcriptional down‐regulation of Brca1 and E‐cadherin by CtBP1 in breast cancer
Carboxyl‐terminal binding protein 1 (CtBP1) is a transcriptional co‐repressor with oncogenic potential. Immunohistochemistry staining using human breast cancer tissue arrays revealed that 92% of invasive ductal breast cancer cases have CtBP1‐positive staining compared to 4% CtBP1‐positive in normal breast tissue. To explore the functional impact of CtBP1 in breast cancer, we examined CtBP1's transcriptional regulation of known tumor suppressors, breast cancer susceptibility gene 1 (Brca1), and E‐cadherin. We found CtBP1 was recruited to the promoter regions of Brca1 and E‐cadherin genes in breast cancer cells. Concomitantly, Brca1 loss was detected in 57% and E‐cadherin loss was detected in 76% of human invasive ductal breast cancers, and correlated with CtBP1 nuclear staining in these lesions. Importantly, siRNA knock down of CtBP1 restored Brca1 and E‐cadherin expression in breast cancer cell lines, implying CtBP1 down‐regulates Brca1 and E‐cadherin genes in human breast cancer. This study provides evidence that although genetic loss of Brca1 and E‐cadherin are infrequent in breast cancer, they are down‐regulated at the transcriptional level by CtBP1 expression. Thus, CtBP1 activation could be a potential biomarker for breast cancer development.
- 16 June 2011
- Published by Wiley in Molecular Carcinogenesis
- Vol. 51 (6) , 500-507
Transcriptional down‐regulation of Brca1 and E‐cadherin by CtBP1 in breast cancer
Carboxyl‐terminal binding protein 1 (CtBP1) is a transcriptional co‐repressor with oncogenic potential. Immunohistochemistry staining using human breast cancer tissue arrays revealed that 92% of invasive ductal breast cancer cases have CtBP1‐positive staining compared to 4% CtBP1‐positive in normal breast tissue. To explore the functional impact of CtBP1 in breast cancer, we examined CtBP1's transcriptional regulation of known tumor suppressors, breast cancer susceptibility gene 1 (Brca1), and E‐cadherin. We found CtBP1 was recruited to the promoter regions of Brca1 and E‐cadherin genes in breast cancer cells. Concomitantly, Brca1 loss was detected in 57% and E‐cadherin loss was detected in 76% of human invasive ductal breast cancers, and correlated with CtBP1 nuclear staining in these lesions. Importantly, siRNA knock down of CtBP1 restored Brca1 and E‐cadherin expression in breast cancer cell lines, implying CtBP1 down‐regulates Brca1 and E‐cadherin genes in human breast cancer. This study provides evidence that although genetic loss of Brca1 and E‐cadherin are infrequent in breast cancer, they are down‐regulated at the transcriptional level by CtBP1 expression. Thus, CtBP1 activation could be a potential biomarker for breast cancer development.
- Open Access
- 6 September 2010
- Published by Springer Nature in Oncogene
- Vol. 29 (50) , 6603-6608
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1
C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic sensory protein, which often represses tumor suppressor genes. Hence, we sought to determine if CtBP1 affects expression of the tumor suppressor Brca1 in head and neck tissue, as downregulation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs). We found that CtBP1 represses Brca1 transcription by binding to the E2F4 site of the Brca1 promoter. Additionally, the recruitment of CtBP1 to the Brca1 promoter is redox-dependent, that is, increased at high NADH levels in hypoxic conditions. Further, immunostaining using a human HNSCC tissue array revealed that nuclear CtBP1 staining began to accumulate in hyperplasic lesions and HNSCCs, this staining correlated with Brca1 downregulation in these lesions. Pharmacological disruption of CtBP1 binding to Brca1 promoter by the antioxidant Tempol, which reduces NADH levels, relieved CtBP1-mediated repression of Brca1, leading to increased DNA repair in HNSCC cells. As tumor cells are generally hypoxic with increased NADH levels, the dynamic control of Brca1 by a ‘metabolic switch’ found in this study not only provides an important link between tumor metabolism and tumor suppressor expression but also suggests a potential chemo preventative or therapeutic strategy for HNSCC by blocking NADH-dependent CtBP1 activity at early stages of HNSCC carcinogenesis.
- 6 September 2010
- Published by Springer Nature in Oncogene
- Vol. 29 (50) , 6603-6608
Open AccessRedox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1
C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic sensory protein, which often represses tumor suppressor genes. Hence, we sought to determine if CtBP1 affects expression of the tumor suppressor Brca1 in head and neck tissue, as downregulation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs). We found that CtBP1 represses Brca1 transcription by binding to the E2F4 site of the Brca1 promoter. Additionally, the recruitment of CtBP1 to the Brca1 promoter is redox-dependent, that is, increased at high NADH levels in hypoxic conditions. Further, immunostaining using a human HNSCC tissue array revealed that nuclear CtBP1 staining began to accumulate in hyperplasic lesions and HNSCCs, this staining correlated with Brca1 downregulation in these lesions. Pharmacological disruption of CtBP1 binding to Brca1 promoter by the antioxidant Tempol, which reduces NADH levels, relieved CtBP1-mediated repression of Brca1, leading to increased DNA repair in HNSCC cells. As tumor cells are generally hypoxic with increased NADH levels, the dynamic control of Brca1 by a ‘metabolic switch’ found in this study not only provides an important link between tumor metabolism and tumor suppressor expression but also suggests a potential chemo preventative or therapeutic strategy for HNSCC by blocking NADH-dependent CtBP1 activity at early stages of HNSCC carcinogenesis.